For Forest, one Bystolic test down, six to go

For Forest, one Bystolic test down, six to go
Forest is hurting from the 2012 patent expiration of depression med Lexapro, but COPD drug Tudorza (aclidinium) and IBS drug Linzess (linaclotide) were both approved this year, and the company's portfolio includes other potential new drugs including …

Full News here – Read more on Medical Marketing and Media

Leave a Reply